Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA FE 1 5 30 versus OVCON 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA FE 1 5 30 versus OVCON 35.
AUROVELA FE 1.5/30 vs OVCON-35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate is a progestin that suppresses gonadotropin release, inhibiting ovulation; ethinyl estradiol is an estrogen that provides feedback inhibition of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), preventing follicular development and ovulation. Additionally, it causes changes in cervical mucus (increased viscosity) and endometrium (reduced receptivity).
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and increases cervical mucus viscosity, impeding sperm penetration.
One tablet orally once daily at the same time each day for 28 consecutive days.
One tablet (35 mcg ethinyl estradiol and 0.4 mg norethindrone) orally once daily.
None Documented
None Documented
Norethindrone: 5-14 hours (terminal); Ethinyl estradiol: 10-20 hours (terminal). Steady-state achieved within 5-7 days; contraceptive efficacy maintained with daily dosing.
Ethinyl estradiol: 5-18 hours (mean ~12 hours, biphasic); norethindrone: 5-14 hours (mean ~8 hours). Terminal half-life relevant for once-daily dosing.
Renal: ~50-60% as metabolites, <10% unchanged; Fecal: ~40-50% via bile; Ethinyl estradiol undergoes enterohepatic recirculation.
Renal 60% (metabolites, glucuronide conjugates), fecal 10%, biliary 5%, remainder via other pathways.
Category C
Category C
Oral Contraceptive
Oral Contraceptive